Form 4: Emergent BioSolutions Director Sujata Tyagi Dayal Reports Stock and Option Grants

Director Sujata Tyagi Dayal reports the acquisition of restricted stock units and stock options in Emergent BioSolutions Inc.

Summary

• On April 30, 2025, Sujata Tyagi Dayal, a director of Emergent BioSolutions Inc., reported transactions involving the company's stock.
• Dayal acquired 34,403 shares of common stock through restricted stock units (RSUs) and disposed of 97,532 shares.
• Additionally, Dayal acquired 15,824 stock options with an exercise price of $5.45, exercisable from April 29, 2032.
• These transactions were part of the company's Stock Incentive Plan for Board and Committee service.
• The RSUs will vest on the day prior to the one-year anniversary of the grant date, contingent on Dayal remaining a board member.

Sentiment

Score: 7

Explanation: The document reflects standard compensation practices, indicating stability and alignment of interests. It's a neutral but positive signal.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting requirements incentivize continued service on the board of directors.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This filing is a routine disclosure of equity grants to a company director, common in publicly traded companies to incentivize and retain board members.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across publicly traded companies.
• The specific amount and terms of the grants are likely benchmarked against peer companies in the biotechnology industry to ensure competitive compensation.
• Companies like Moderna, BioNTech, and Novavax also utilize stock options and RSUs as part of their director compensation packages.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Emergent BioSolutions, Director, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership, Equity Securities